ABX.TO vs. AZN
ABX.TO (Barrick Gold Corporation) and AZN (AstraZeneca PLC) are both stocks. ABX.TO operates in Gold (Basic Materials), while AZN operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, ABX.TO returned 10.36%/yr vs 17.04%/yr for AZN. At a 0.09 correlation, their price movements are largely independent.
Performance
ABX.TO vs. AZN - Performance Comparison
Loading charts...
Different Trading Currencies
ABX.TO is traded in CAD, while AZN is traded in USD. To make them comparable, the AZN values have been converted to CAD using the latest available exchange rates.
Returns By Period
In the year-to-date period, ABX.TO achieves a -7.65% return, which is significantly lower than AZN's 3.75% return. Over the past 10 years, ABX.TO has underperformed AZN with an annualized return of 10.36%, while AZN has yielded a comparatively higher 17.04% annualized return.
ABX.TO
- 1D
- -0.96%
- 1M
- -7.27%
- YTD
- -7.65%
- 6M
- -2.56%
- 1Y
- 100.69%
- 3Y*
- 37.09%
- 5Y*
- 17.25%
- 10Y*
- 10.36%
AZN
- 1D
- 1.07%
- 1M
- 2.44%
- YTD
- 3.75%
- 6M
- 5.00%
- 1Y
- 31.58%
- 3Y*
- 11.50%
- 5Y*
- 15.03%
- 10Y*
- 17.04%
ABX.TO vs. AZN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ABX.TO Barrick Gold Corporation | -7.65% | 173.89% | -4.69% | 5.66% | 1.28% | -13.98% | 21.72% | 31.81% | 2.67% | -14.89% |
AZN AstraZeneca PLC | 3.80% | 36.76% | 7.80% | -0.97% | 26.69% | 19.60% | 0.67% | 30.09% | 23.44% | 24.09% |
Correlation
The correlation between ABX.TO and AZN is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jul 7, 2006 | 0.09 |
Fundamentals
ABX.TO:
CA$91.34B
AZN:
$286.33B
ABX.TO:
CA$3.60
AZN:
$6.66
ABX.TO:
15.16
AZN:
27.56
ABX.TO:
0.17
AZN:
0.04
ABX.TO:
4.86
AZN:
4.74
ABX.TO:
3.34
AZN:
6.05
ABX.TO:
CA$19.02B
AZN:
$60.44B
ABX.TO:
CA$10.15B
AZN:
$49.37B
ABX.TO:
CA$12.44B
AZN:
$20.47B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABX.TO vs. AZN — Risk / Return Rank
ABX.TO
AZN
ABX.TO vs. AZN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Barrick Gold Corporation (ABX.TO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ABX.TO | AZN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.05 | ||
| Sortino ratioReturn per unit of downside risk | +0.62 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.23 | +0.13 |
| Calmar ratioReturn relative to maximum drawdown | 3.55 | 2.21 | +1.34 |
| Martin ratioReturn relative to average drawdown | 9.00 | 5.50 | +3.49 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ABX.TO | AZN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.28 | 1.23 | +1.05 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.50 | 0.61 | -0.11 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | 0.66 | -0.37 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.10 | 0.43 | -0.32 |
Drawdowns
ABX.TO vs. AZN - Drawdown Comparison
The maximum ABX.TO drawdown since its inception was -84.65%, which is greater than AZN's maximum drawdown of -49.50%. Use the drawdown chart below to compare losses from any high point for ABX.TO and AZN.
Loading charts...
Drawdown Indicators
| ABX.TO | AZN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.65% | -49.50% | -35.15% |
Max Drawdown (1Y)Largest decline over 1 year | -28.49% | -14.39% | -14.10% |
Max Drawdown (3Y)Largest decline over 3 years | -28.49% | -25.38% | -3.11% |
Max Drawdown (5Y)Largest decline over 5 years | -43.11% | -25.38% | -17.73% |
Max Drawdown (10Y)Largest decline over 10 years | -56.74% | -26.18% | -30.56% |
Current DrawdownCurrent decline from peak | -23.16% | -10.24% | -12.92% |
Average DrawdownAverage peak-to-trough decline | -40.47% | -13.30% | -27.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.23% | 5.77% | +5.46% |
Volatility
ABX.TO vs. AZN - Volatility Comparison
Barrick Gold Corporation (ABX.TO) has a higher volatility of 16.64% compared to AstraZeneca PLC (AZN) at 7.48%. This indicates that ABX.TO's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ABX.TO | AZN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.64% | 7.48% | +9.16% |
Volatility (6M)Calculated over the trailing 6-month period | 34.09% | 17.93% | +16.16% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.43% | 25.95% | +18.48% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 34.52% | 24.83% | +9.69% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.90% | 25.75% | +10.15% |
Dividends
ABX.TO vs. AZN - Dividend Comparison
ABX.TO's dividend yield for the trailing twelve months is around 2.32%, less than AZN's 2.90% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABX.TO Barrick Gold Corporation | 2.32% | 1.22% | 2.46% | 2.27% | 4.77% | 3.96% | 1.33% | 0.60% | 1.17% | 0.72% | 0.47% | 1.43% |
AZN AstraZeneca PLC | 2.90% | 1.70% | 2.27% | 2.15% | 2.12% | 2.35% | 2.80% | 2.81% | 3.69% | 3.95% | 5.01% | 4.06% |
Financials
ABX.TO vs. AZN - Financials Comparison
This section allows you to compare key financial metrics between Barrick Gold Corporation and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ABX.TO vs. AZN - Profitability Comparison
ABX.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Barrick Gold Corporation reported a gross profit of 2.97B and revenue of 5.16B. Therefore, the gross margin over that period was 57.5%.
AZN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.
ABX.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Barrick Gold Corporation reported an operating income of 2.93B and revenue of 5.16B, resulting in an operating margin of 56.7%.
AZN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.
ABX.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Barrick Gold Corporation reported a net income of 1.58B and revenue of 5.16B, resulting in a net margin of 30.5%.
AZN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.
Frequently Asked Questions
ABX.TO and AZN have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for ABX.TO and AZN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer